Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 9, 2026

Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde

View original at globenewswire.com

Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Patient safety remains our priority
60% confidence
Based on adverse events related to secondary hematologic malignancies, risks could outweigh potential benefits for patients in this treatment regimen
60% confidence
Patient safety remains our priority despite extremely disappointing outcome
60% confidence
Emerging data from the confirmatory study highlighted a more unfavorable safety profile compared to what was previously observed during clinical evaluation
60% confidence
Emerging data from the confirmatory study highlighted a more unfavorable safety profile compared to what was previously observed during clinical evaluation
60% confidence
Based on adverse events related to secondary hematologic malignancies, the risks could exceed potential benefits for patients in this treatment regimen
60% confidence
The withdrawal should not impact the company's financial guidance
60% confidence
Ipsen will work closely with investigators and clinical teams to support patients through next steps and transition plans
60% confidence
The withdrawal is not expected to impact the company's financial guidance
60% confidence